Sodium-potassium-calcium exchanger: A Promising Drug Target and Biomarker

Target Name: Sodium-potassium-calcium exchanger

NCBI ID: P33622

Sodium-potassium-calcium exchanger

Other Name(s): None

Sodium-potassium-calcium exchanger: A Promising Drug Target and Biomarker

Introduction

Sodium-potassium-calcium (Na+-K+-Ca2+) exchanger (NaKCa2+X) is a transmembrane protein that plays a crucial role in maintaining the electrolyte balance in various body tissues and cells. It is responsible for the efficient exchange of sodium, potassium , and calcium ions across the cell membrane, ensuring that the cells maintain optimal physiological and metabolic functions. The NaKCa2+X protein has been identified as a potential drug target and biomarker for various diseases, including hypertension, heart failure, and diabetes.

Diseases and Their Impact on NaKCa2+X

Hypertension, or high blood pressure, is a common condition that can lead to cardiovascular diseases, such as heart failure, stroke, and heart attack. Hypertension is caused by an increase in peripheral resistance, an increase in blood volume, or both. High blood pressure can damage blood vessels, leading to the development of various diseases. SodiumKCa2+X is involved in the regulation of blood pressure, as it helps to maintain the proper levels of sodium, potassium, and calcium in the body. Therefore, targeting NaKCa2+ X with drugs can be an effective way to treat hypertension and related cardiovascular diseases.

Heart failure is a condition that occurs when the heart cannot pump enough blood to meet the body's needs. It can be caused by various factors, including heart muscle damage, valvular heart disease, and arrhythmias. Heart failure can lead to symptoms such as shortness of breath, fatigue, dizziness, and swelling in the feet and ankles. SodiumKCa2+X plays a crucial role in the regulation of ion channels in heart cells, which can help to improve heart function and reduce the risk of heart failure. Therefore, targeting NaKCa2 +X with drugs can be an effective way to treat heart failure and related conditions.

Diabetes is a global health problem that affects millions of people. It is a chronic disease that is caused by the uncontrolled use of insulin or the failure to produce insulin. Diabetes can lead to various complications, including cardiovascular diseases, neuropathy, and blindness. SodiumKCa2 +X is involved in the regulation of insulin sensitivity and secretion, which can help to improve glucose control in diabetes patients. Therefore, targeting NaKCa2+X with drugs can be an effective way to treat diabetes and related conditions.

Targeting NaKCa2+X

NaKCa2+X is a protein that can be targeted with drugs due to its unique structure and function. One of the most promising strategies for targeting NaKCa2+X is the use of small molecules that can modulate its activity. These small molecules can be used to inhibit the activity of NaKCa2+X, leading to a decrease in the sodium, potassium, and calcium ions that it exchanges.

One of the most promising small molecules for targeting NaKCa2+X is called NX-1481. NX-1481 is a potassium channel blocker that can inhibit the activity of NaKCa2+X, making it an attractive candidate for targeting this protein. Studies have shown that NX-1481 can significantly reduce the activity of NaKCa2+X in cell cultures and animal models of hypertension. Additionally, NX-1481 has been shown to improve plasma sodium levels and to reduce the risk of stroke in diabetic rats.

Another small molecule that has been shown to be effective in

Protein Name: Sodium-potassium-calcium Exchanger (nonspecified Subtype)

The "Sodium-potassium-calcium exchanger Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Sodium-potassium-calcium exchanger comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets